Member Info for Escapetohome

Likely to fall to all time low.

Uncertainty created.

DOWN.

Doesn't look like you'll get $20 test.

Wrong call.

I view it as management talking the share down. That info should be in an rns, agree as price sensitive.

Why talk the shares down? Because , with the risks involved a raising at the former price was unpalatable for interested parties.

I'm beginning to lose confidence here. I won't be buying further shares.

I can't say I'm that impressed.

Oh dear tut tut.

Why not buy them a Big Mac, they must be ravenous now , and reduced salary for the year, if true

Unless they keep to the timeframe they themselves informed, they become a company which destroys their value raising money at lower and lower prices.

- 20 percent if no comes

- 10 to 15 percent Rns advising of delays but some good news.

- 50 to 60 percent on no deals RNs

That's my guess.

Hmm might go in for some cardiogeni , repeat some, when they come to aim depending on success of Roquefort.

Tried to buy a few already actually but my broker doesn't deal in early asqe stocks.

I like to keep my holdings small so I'm not emotionally impacted if something does not go to plan. I don't get worried or constantly demanding explanations.

Huh, in fact I already got some cardiogeni as I invested in Celixir on crowd cube , but they never issued me the share certificate of cardiogeni, I guess because my holding is too small.

Waiting patiently for the 31st I expect.

Surely , by then, that's when we can expect some news. Confirmation or further delay on at least one of the deals.

DOWN. The share price is doing the talking here.

It ain't pretty.

No doubt Carol will be visiting India soon. Jesus wept.

Led by experienced Pharma CEO Caroline Fontier, with a history of significant trade sales exceeding US$750 million.

Pleiades will continue to work with PDC-CRO as its clinical research partner in the Middle East.

Roquefort refer to them as 'Pleiades Pharma Limited' , whilst the indian outfit has 'therapeutics' in its name.

Are you sure you got the right company with your indian assertion?

The names are slightly different, hence I was unsure if the injan one was the correct.

When I looked up the head honcho of the company ( some time ago now ) she seemed to be based in Canada/USA.

Are you spouting CONjecture or do you actually know?

I don't.

The Company remains focused on completing the Lyramid and Oncogeni transactions which, on completion, will validate our initial business model of acquiring early-stage pre-clinical assets and then selling them with a solid medium return on investment. The current headwinds facing biotech companies, particularly those whose assets are in the pre-clinical phase, dictates that an adjustment in business model is required. Accordingly, the Company is leveraging off the abovenamed material transactions and change in leadership to pivot its focus towards acquiring clinical stage assets and/or revenue generating life science businesses. This is an exciting transition stage for the Company and we look forward to updating the market as it progresses."

Completion of the transaction with Pleiades will give the Company and its shareholders exposure to a well-funded company with a significant portfolio of pre-clinical and clinical assets including a Phase 3 stage cell therapy and Phase 2 stage vaccine. A future trade-sale or stock exchange listing of Pleiades may result in a significant cash windfall to the Company which could be distributed to shareholders as a special dividend.

There'll be a riot if this doesn't multibag.

Suckin' em in.

Falling now.

DOWN.

Suckin' em in.

T-1 ....AND Counting.

Many have risen, many more have crashed and burned.